• 1
    Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7: 110.
  • 2
    Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004; 329: 972975.
  • 3
    Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 609621.
  • 4
    Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care 2006; 12: S3S16.
  • 5
    Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295: 23742384.
  • 6
    Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004; 34: 209223.
  • 7
    Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 408415.
  • 8
    Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 2007; 25: 611613.
  • 9
    Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007; 13: 806813.
  • 10
    Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
  • 11
    Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989; 262: 28792886.
  • 12
    Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 11721177.
  • 13
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 13391341.
  • 14
    Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 12531258.
  • 15
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
  • 16
    Earle CC, Evans WK. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control 1997; 1: 282288.
  • 17
    Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module. Semin Oncol 1997; 24: S7S56, S57–S63.
  • 18
    Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 2006; 27: 895901.
  • 19
    Neymark N, Lianes P, Smit EF, van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005; 23: 11551166.
  • 20
    American Cancer Society. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
  • 21
    Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007; 110: 678685.
  • 22
    Avritscher EB, Cantor SB, Shih YC, et al. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 2004; 12: 531536.
  • 23
    Luomanmäki K, Grankvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 1996; 240: 8592.
  • 24
    Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191202.
  • 25
    Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291297.
  • 26
    Halpern MT, Dirani R, Schmier JK. Impacts of a smoking cessation benefit among employed populations. J Occup Environ Med 2007; 49: 1121.
  • 27
    Stokey E, Zeckhauser R. Project evaluation: benefit-cost analysis, in Stokey E, Zeckhauser R (eds). A Primer for Policy Analysis. 1st ed. New York, NY: WW. Norton & Company, Inc.; 1978: 134158.
  • 28
    Shibley L, Brown M, Schuttinga J, et al. Cisplatin-based combination chemotherapy in the treatment of advanced-stage testicular cancer: cost-benefit analysis. J Natl Cancer Inst 1990; 82: 186192.
  • 29
    Leighl NB, Tsao WS, Zawisza DL, et al. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006; 51: 115121.
  • 30
    Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 1998; 83: 25882596.
  • 31
    Ossa DF, Briggs A, McIntosh E, et al. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 2007; 25: 223237.
  • 32
    Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ 2004; 13: 453459.
  • 33
    O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ 2002; 11: 175180.
  • 34
    Ng R, Hasan B, Mittmann N, et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer—a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 22562261.
  • 35
    Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 130.
  • 36
    Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559575.
  • 37
    Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43: 203220.
  • 38
    Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996; 34: 702722.
  • 39
    Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 1995; 7: 503520.
  • 40
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 33023317.
  • 41
    Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 131.
  • 42
    Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332342.
  • 43
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 16371641.
  • 44
    Hayman J, Weeks J, Mauch P. Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int J Radiat Oncol Biol Phys 1996; 35: 827841.
  • 45
    Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11: 9095.
  • 46
    Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Making 2000; 20: 451467.
  • 47
    Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 3340.
  • 48
    Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125152.
  • 49
    Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 2008; 26: 925933.
  • 50
    Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007; 25: 634641.
  • 51
    Neumann PJ. Budget impact analyses get some respect. Value Health 2007; 10: 324325.
  • 52
    Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health 2007; 10: 336347.
  • 53
    Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Future Drugs 2005; 5: 6579.
  • 54
    Hind D, Ward S, De Nigris E, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007; 11: 1134.
  • 55
    Zbrozek AS, Cantor SB, Cardenas MP, Hill DP Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994; 51: 15551563.
  • 56
    Rubenstein EB, Elting LS. Pharmacoeconomic analyses: whose perspective counts and costs the most? Am J Hosp Pharm 1994; 51: 15641569.
  • 57
    Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 2001; 19: 220230.
  • 58
    Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006; 24: 11331142.
  • 59
    Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006; 24: 11571162.
  • 60
    Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353: 15161522.
  • 61
    Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics 2006; 24: 11631168.
  • 62
    Emanuel EJ, Fuchs VR, Garber AM. Essential elements of a technology and outcomes assessment initiative. JAMA 2007; 298: 13231325.
  • 63
    Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25: 180186.
  • 64
    Berenson A. A cancer drug shows promise, at a price that many can't pay. New York Times. February 15, 2006. Available at: Accessed May 4, 2008.
  • 65
    Chen AY, Halpern MT, Schrag NM, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 2008; 100: 462474.
  • 66
    Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008; 9: 222231.
  • 67
    Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008; 58: 931.
  • 68
    Bennett CL, Lee T. Economic analysis of cancer treatment, in Abeloff MD, Armitage JO, Niederhuber JE, et al (eds). Clinical Oncology. 3rd ed. Philadelphia, PA: Elsevier Inc.; 2004: 395405.
  • 69
    Hillner BE, Hayman JA. Cost and cost-effectiveness considerations, in Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 14971513.
  • 70
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, NY: Oxford University Press; 1997.
  • 71
    Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. 1st ed. Oxford, UK: Oxford University Press; 2004.
  • 72
    Muennig P. Cost-Effectiveness Analysis in Health: A Practical Approach. 2nd ed. San Francisco, CA: Jossey-Bass; 2008.